We are live on ! Find out more
KITE

Kite Pharma
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

155 hedge funds and large institutions have $1.87B invested in Kite Pharma in 2015 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 62 increasing their positions, 49 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

155% more capital inflows, than outflows

Capital inflows: $359M | Capital outflows: $141M

27% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 49

21% more call options, than puts

Call options by funds: $41M | Put options by funds: $34M

7.14% more ownership

Funds ownership: 68.95% → 76.09% (+7.1%)

5% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 22

0% more funds holding

Funds holding: 155 → 155 (0)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
155
Holders Change
–
Holders Change %
0%
% of All Funds
4.32%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.17%
New
23
Increased
62
Reduced
49
Closed
22
Calls
$41​M
Puts
$34​M
Net Calls
+$7.03​M
Net Calls Change
+$22.4​M

KITE Hedge Fund Activity: Q3 2015 in Review

155 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma (KITE) for Q3 2015, worth a combined $1.87B — up 1.7% from $1.84B a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new KITE positions and 22 closed out — a net gain of 1 holder — while 62 added to existing stakes and 49 trimmed.

The largest buyer was Viking Global Investors, adding an estimated $113M. The largest seller was Frontier Capital Management, cutting an estimated $16.2M.

  • 155 institutional investors held Kite Pharma (KITE) as of Q3 2015, unchanged from Q2 2015.
  • Funds reported $1.87B of Kite Pharma stock for Q3 2015, up 1.7% quarter-over-quarter.
  • 23 funds opened new Kite Pharma positions in Q3 2015 and 22 closed out, a net change of +1 holder.
  • The largest Kite Pharma buyer in Q3 2015 was Viking Global Investors, an estimated $113M added.
  • The largest Kite Pharma seller in Q3 2015 was Frontier Capital Management, an estimated $16.2M sold.

Based on aggregated 13F filings for Q3 2015.